These novel physiopharmacological properties for the AnxA1 and FPR2/ALX pathway increase our understanding of the cellular intravascular events typical of stroke and open new avenues for an attractive therapeutic treatment strategy not only for patients with stroke but also for patients susceptible to stroke. This evidence concerns the gene FPR2 and stroke disorder.